Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ImmunityBio, Inc. (IBRX)

ImmunityBio's ANKTIVA Gets UAE Marketing Authorization for Two Cancer Indications

Neutral Impact 2 of 5 legal/regulatory Written later

ImmunityBio announced on July 29, 2026 that the UAE's Emirates Drug Establishment granted marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer and in metastatic non-small cell lung cancer after checkpoint inhibitor failure. The filing says this brings ANKTIVA's regulatory footprint to 34 countries, but it contains no revenue, sales, or financial results, so the direct financial effect on shareholders is not quantified.

Key points

  • UAE authorization granted with first registration in July 2026 and validity through July 2031.
  • Bladder cancer indication (with BCG) covers CIS with or without papillary tumors, described as the first worldwide to span the full spectrum of BCG-unresponsive disease.
  • Lung cancer indication (with checkpoint inhibitors) covers metastatic NSCLC after progression; median overall survival was 14.6 months in the 79-patient QUILT-3.055 study.
  • ImmunityBio's regional partner in the UAE is Modern Pharmaceutical Company.

The filing

CompanyImmunityBio, Inc. (IBRX)
Form8-K, current report
Filed with the SECJul 30, 2026, 5:19 PM ET
Accession number0001326110-26-000071

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.